Literature DB >> 31319341

Brain serotonin transporter binding, plasma arachidonic acid and depression severity: A positron emission tomography study of major depression.

Manesh Gopaldas1, Francesca Zanderigo2, Serena Zhan3, R Todd Ogden4, Jeffrey M Miller2, Harry Rubin-Falcone2, Thomas B Cooper5, Maria A Oquendo6, Gregory Sullivan7, J John Mann8, M Elizabeth Sublette9.   

Abstract

BACKGROUND: Serotonin transporter (5-HTT) binding and polyunsaturated fatty acids (PUFAs) are implicated in major depressive disorder (MDD). Links between the two systems in animal models have not been investigated in humans.
METHODS: Using positron emission tomography (PET) and [11C]DASB, we studied relationships between 5-HTT binding potential and plasma levels of PUFAs docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and arachidonic acid (AA) in medication-free MDD patients (n = 21). PUFAs were quantified using transesterification and gas chromatography. Binding potential BPP, and alternative outcome measures BPF and BPND, were determined for [11C]DASB in six a priori brain regions of interest (ROIs) using likelihood estimation in graphical analysis (LEGA) to calculate radioligand total distribution volume (VT), and a validated hybrid deconvolution approach (HYDECA) that estimates radioligand non-displaceable distribution volume (VND) without a reference region. Linear mixed models used PUFA levels as predictors and binding potential measures as outcomes across the specified ROIs; age and sex as fixed effects; and subject as random effect to account for across-region binding correlations. As nonlinear relationships were observed, a quadratic term was added to final models.
RESULTS: AA predicted both 5-HTT BPP and depression severity nonlinearly, described by an inverted U-shaped curve. 5-HTT binding potential mediated the relationship between AA and depression severity. LIMITATIONS: Given the small sample and multiple comparisons, results require replication.
CONCLUSIONS: Our findings suggest that AA status may impact depression pathophysiology through effects on serotonin transport. Future studies should examine whether these relationships explain therapeutic effects of PUFAs in the treatment of MDD.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Arachidonic acid; Depression; PET; Polyunsaturated fatty acids; Serotonin transporter; [(11)C]DASB

Mesh:

Substances:

Year:  2019        PMID: 31319341      PMCID: PMC6886679          DOI: 10.1016/j.jad.2019.07.035

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  87 in total

1.  In vivo brain incorporation of [1-14C]arachidonate in awake rats, with or without cholinergic stimulation, following unilateral lesioning of nucleus basalis magnocellularis.

Authors:  T Nariai; J J DeGeorge; Y Lamour; S I Rapoport
Journal:  Brain Res       Date:  1991-09-13       Impact factor: 3.252

2.  Midbrain binding of [123I]nor-beta-CIT in atypical depression.

Authors:  Soili Lehto; Tommi Tolmunen; Mikko Joensuu; Pirjo Irmeli Saarinen; Ritva Vanninen; Pasi Ahola; Jari Tiihonen; Jyrki Kuikka; Johannes Lehtonen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-04-27       Impact factor: 5.067

Review 3.  Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.

Authors:  Stanley I Rapoport
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

4.  Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis.

Authors:  G Lepage; E Levy; N Ronco; L Smith; N Galéano; C C Roy
Journal:  J Lipid Res       Date:  1989-10       Impact factor: 5.922

5.  [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder.

Authors:  M Willeit; N Praschak-Rieder; A Neumeister; W Pirker; S Asenbaum; O Vitouch; J Tauscher; E Hilger; J Stastny; T Brücke; S Kasper
Journal:  Biol Psychiatry       Date:  2000-03-15       Impact factor: 13.382

6.  Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain.

Authors:  H Ito; Y Sudo; T Suhara; Y Okubo; C Halldin; L Farde
Journal:  Neuroimage       Date:  2001-03       Impact factor: 6.556

7.  Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Authors:  Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2013-03-01       Impact factor: 13.382

8.  Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography.

Authors:  Maria A Oquendo; Ramin S Hastings; Yung-Yu Huang; Norman Simpson; R Todd Ogden; Xian-Zhang Hu; David Goldman; Victoria Arango; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Arch Gen Psychiatry       Date:  2007-02

9.  Modeling considerations for in vivo quantification of the dopamine transporter using [(11)C]PE2I and positron emission tomography.

Authors:  Christine DeLorenzo; J S Dileep Kumar; Francesca Zanderigo; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-20       Impact factor: 6.200

10.  Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB.

Authors:  Sudhakar Selvaraj; Naga Venkatesha Murthy; Zubin Bhagwagar; Subrata K Bose; Rainer Hinz; Paul M Grasby; Philip J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

View more
  5 in total

1.  Serotonin transporter binding in major depressive disorder: impact of serotonin system anatomy.

Authors:  Elizabeth A Bartlett; Francesca Zanderigo; Denise Shieh; Jeffrey Miller; Patrick Hurley; Harry Rubin-Falcone; Maria A Oquendo; M Elizabeth Sublette; R Todd Ogden; J John Mann
Journal:  Mol Psychiatry       Date:  2022-04-29       Impact factor: 13.437

2.  The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta-analysis of the Literature.

Authors:  Beina Chen; Manman Zhang; Ming Ji; Wenliang Gong; Binjie Chen; Robert Zorec; Matjaž Stenovec; Alexei Verkhratsky; Baoman Li
Journal:  Neurochem Res       Date:  2021-02-01       Impact factor: 3.996

3.  The antidepressant effects and serum metabonomics of bifid triple viable capsule in a rat model of chronic unpredictable mild stress.

Authors:  Qinpeng Bu; Jingkai Zhang; Xiang Guo; Yifei Feng; Huan Yan; Weimin Cheng; Zhitao Feng; Meiqun Cao
Journal:  Front Nutr       Date:  2022-09-15

4.  Fish oil supplementation alleviates metabolic and anxiodepressive effects of diet-induced obesity and associated changes in brain lipid composition in mice.

Authors:  Geneviève Demers; Jerome Roy; Arturo Israel Machuca-Parra; Zahra Dashtehei Pour; Diane Bairamian; Caroline Daneault; Christine Des Rosiers; Guillaume Ferreira; Thierry Alquier; Stephanie Fulton
Journal:  Int J Obes (Lond)       Date:  2020-06-16       Impact factor: 5.095

5.  DHA Supplementation of Obese Rats throughout Pregnancy and Lactation Modifies Milk Composition and Anxiety Behavior of Offspring.

Authors:  Elena Zambrano; Guadalupe L Rodríguez-González; Luis A Reyes-Castro; Claudia J Bautista; Diana C Castro-Rodríguez; Gimena Juárez-Pilares; Carlos A Ibáñez; Alejandra Hernández-Rojas; Peter W Nathanielsz; Sara Montaño; Armando Arredondo; Fengyang Huang; Francisco Bolaños-Jiménez
Journal:  Nutrients       Date:  2021-11-26       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.